Post by i-Pharm Consulting

🔬 GSK is acquiring Nuvalent for $10.6 billion in a deal built around lung cancer The Boston-based biotech brings two late-stage assets, both targeting non-small cell lung cancer (NSCLC), both under FDA review for potential 2026 approval, and both with multi-blockbuster potential. A third asset is in Phase I trials. What makes this notable isn't just the price tag. The forms of NSCLC Nuvalent primarily targets affect non-smoking adults in their 40s and 50s. A well-defined patient population that current treatments continue to underserve through resistance mutations and tolerability issues. GSK isn't entering this space on a bet. Both lead assets already have FDA Breakthrough Therapy and Orphan Drug Designations, with FDA decision dates set for September and November this year. Watch this space… #Oncology #LifeSciences #Pharma #Biopharma #Acquisition